Update on the treatment of tuberculosis and latent tuberculosis infection
- PMID: 15941808
- DOI: 10.1001/jama.293.22.2776
Update on the treatment of tuberculosis and latent tuberculosis infection
Erratum in
- JAMA. 2005 Jul 13;294(2): 182. Dosage error in article text
Abstract
Tuberculosis (TB) has emerged as a global public health epidemic. Despite decreasing numbers of cases in the United States since 1992, TB remains a serious public health problem among certain patient populations and is highly prevalent in many urban areas. The responsibility for prescribing an appropriate drug regimen and ensuring that treatment is completed is assigned to the public health program or the clinician not to the patient. The initial prescribed regimen for the treatment of TB usually consists of 4 drugs: isoniazid, rifampin, pyrazinamide, and ethambutol. The minimum length for the treatment of drug-susceptible TB with a rifampin-based regimen is 6 to 9 months. Providing medications directly to the patient and watching him/her swallow the anti-TB drugs, which is termed directly observed therapy, is recommended for all patients diagnosed with TB and can help ensure higher completion rates, prevent the emergence of drug resistant TB, and enhance TB control. There has been renewed interest in the treatment of those with latent TB infection as a TB-control strategy in the United States for eliminating the large reservoir of individuals at risk for progression to TB. The 2 broad categories of persons who should be tested for latent TB infection are those who are likely to have been recently infected (such as contacts to infectious TB cases) and persons who are at increased risk of progression to TB disease following infection with Mycobacterium tuberculosis (eg, human immunodeficiency virus infection and selected medical conditions; recent immigrants to the United States from high TB-burden countries). The preferred regimen for the treatment of latent TB infection is 9 months of isoniazid. There is now renewed interest in and great need for the development of new drugs to treat TB and latent TB infection.
Similar articles
-
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.J Assoc Physicians India. 2006 Mar;54:219-34. J Assoc Physicians India. 2006. PMID: 16800350
-
Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.MMWR Recomm Rep. 1998 Oct 30;47(RR-20):1-58. MMWR Recomm Rep. 1998. PMID: 9809743
-
Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control.Clin Infect Dis. 2000 Jul;31(1):120-4. doi: 10.1086/313891. Epub 2000 Jul 25. Clin Infect Dis. 2000. PMID: 10913407 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Update on the treatment of tuberculosis.Am Fam Physician. 2008 Aug 15;78(4):457-65. Am Fam Physician. 2008. PMID: 18756652
Cited by
-
A rare cause of duodenal stricture.BMJ Case Rep. 2011 Feb 8;2011:bcr1020103379. doi: 10.1136/bcr.10.2010.3379. BMJ Case Rep. 2011. PMID: 22715182 Free PMC article.
-
Multidrug-resistant tuberculosis in military recruits.Emerg Infect Dis. 2006 May;12(5):760-2. doi: 10.3201/eid1205.050708. Emerg Infect Dis. 2006. PMID: 16704832 Free PMC article.
-
Prevalence and incidence of latent tuberculosis infection in georgian healthcare workers.PLoS One. 2013;8(3):e58202. doi: 10.1371/journal.pone.0058202. Epub 2013 Mar 25. PLoS One. 2013. PMID: 23536789 Free PMC article.
-
Saudi guidelines for testing and treatment of latent tuberculosis infection.Ann Saudi Med. 2010 Jan-Feb;30(1):38-49. doi: 10.4103/0256-4947.59373. Ann Saudi Med. 2010. PMID: 20103957 Free PMC article.
-
Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays.BMC Infect Dis. 2011 Sep 30;11:264. doi: 10.1186/1471-2334-11-264. BMC Infect Dis. 2011. PMID: 21962029 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical